GE HealthCare has launched Signa Magnus, a head-only magnetic resonance (MR) scanner, to advance the field of neuroscience.
Signa Magnus, pending US Food and Drug Administration (FDA) 510(k) approval, is designed to expand MR research in complex imaging procedures in neurology, oncology and psychiatry.
US-based GE HealthCare said that the device addresses challenges conventional whole-body MR systems pose.
The MR scanner advances the medical technology company’s vision for an advanced 3.0T MR imaging system for head-only neurological and oncological research imaging.
The system is engineered to provide a thorough exploration of brain microstructure, microvasculature, and function.
Through Signa Magnus, GE HealthCare plans to empower neuroscientists, neurologists, neuroradiologists, and oncologists to advance the diagnosis, comprehension, and treatment of complex disorders.
GE HealthCare MR CEO Kelly Londy said: “With Signa Magnus, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care.
“This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what’s possible in MR imaging.
“The potential impact of Signa Magnus on patient outcomes and our understanding of the human brain is profound.”
Signa Magnus has HyperG gradient technology to offer better gradient performance. The technology features 300 mT/m and 750 T/m/s capabilities that facilitate the detection of minute details previously beyond reach.
Researchers can use this MR scanner to push the boundaries of advanced anatomical, diffusion, and functional techniques, supported by GE HealthCare’s latest deep-learning algorithms.
Additionally, its asymmetric gradient design ensures diffusion performance, achieving high B-value diffusion with short echo times (TEs), refining the understanding of neural architecture, GE HealthCare said.
Furthermore, many existing GE HealthCare 3.0T systems are upgradeable to Signa Magnus to offer potential customers cost savings on capital expenses.
In March 2024, the investigational Magnus system was successfully installed at Brigham and Women’s Hospital.
Recently, the medical technology company unveiled its Revolution RT to increase imaging accuracy in oncology care.
